Could it be possible that a simple molecular discovery enables the beta prototype for cavity proofing teeth, a molecule that could be added to cavity inducing products like sweets, candies, chewing gum and even soda pop? Considering everywhere that technology and medical breakthroughs have taken mankind, nothing is impossible at this point. And in answer to the question poised above, a solution of this sort is already well in the works.
Research Began in 2005
Back in 2005, research began on such a molecule. The goal was to develop something that inhibited bacterial growth in the mouth. Bacteria are what cause tooth decay. There are more than 100 bacterium that inhabit the mouth and that generally like to feed off the sugars we ingest. When bacteria consume these sugars, they emit acidic compounds that eat away or demineralize the protective coating on the teeth (enamel), and that ultimately contribute to tooth decay and rot. Additionally, bacteria emit an odoriferous compound that is the key cause of bad breath (halitosis).
Basis of the Solution
The hypothesis of such a compound would be to eradicate and eliminate bacteria that contribute to tooth decay and halitosis. Two researchers, José Córdoba of Yale University, and Erich Astudillo of the Universidad de Santiago in Chile, set out to answer this question and to see if they could create such a compound that combated bacteria in the mouth at the molecular level. They’ve discovered a molecule that does just that, something they have affably named “Keep 32.” It’s a powerful antibacterial agent that can be added to many types of sugary foods known to cause cavities. It takes about one minute to fully cleanse the mouth and prevent cavities from bacteria.
Human, Clinical Trials Forthcoming
The primary hang-up for the duo will be getting the Keep 32 approved in a similar category to fluoride; which helps remineralize teeth, and that works to combat Streptococcus Mutans (the most common bacteria in the mouth). The molecule is set to enter human test trials over the months to come. Pending the outcome of those trials, and the efficacy that’s established at the clinical level, it could very well end up being licensed to major toothpaste makers like Colgate or Proctor and Gamble. The only setback would be the FDA labeling this molecule as an antibiotic—which would place it in an entirely different and controlled and regulated category that may prevent it from being as widespread in use as the makers intended.
